摘要
目的:探讨基于哮喘症状控制水平分级管理系统的药学规范化管理新模式对哮喘患儿的临床控制水平、依从性及生活质量的影响。方法:随机抽取2016年10月至2018年10月我院呼吸科门诊或住院部符合纳入标准的学龄前哮喘患儿。将所有患儿资料录入系统,对管理组患儿进行定期随访及药学干预,依据病情变化评估治疗效果,调整治疗方案及随访方案。结果:管理组和对照组1年后哮喘控制水平、转化率和控制率比较差异有统计学意义(P<0. 05),管理组的控制率达83. 33%,转化率达82. 50%。管理组和对照组1年内发作次数、住院次数和急诊就诊次数比较差异有统计学意义(P <0. 01)。管理组肺功能指标第1秒用力呼气容积百分比(FEV1%)、最高呼气流速百分比(PEF%)在治疗6个月和12个月后均高于对照组,差异有统计学意义(P<0. 01)。管理组和对照组1年后家长知信行水平、患儿用药依从性比较差异均有统计学意义(P<0. 01)。结论:基于哮喘症状控制水平分级管理系统的药学规范化管理新模式对控制哮喘患儿临床症状、降低未来风险及提高生命质量等的效果显著,可作为工作模式进一步推广。
Objective:To probe into the effects of new model of pharmaceutical standardization management for asthma children based on asthma symptom control level grading management system on the clinical control level,compliance and quality of life of children with asthma.Methods:Preschool children with asthma who met the inclusion criteria in the outpatient or inpatient department of respiratory department of our hospital from Oct.2016 to Oct.2018 were randomly selected.All of the data were recorded into the system,and children in the management group were followed up regularly and the pharmaceutical intervention was carried out.The treatment effects was evaluated according to the changes of disease conditions,the treatment regimen and follow-up plan were adjusted.Results:After 1 year,there were statistically significant differences between the management group and the control group in asthma control level,conversion rate and control rate(P<0.05).The control rate and conversion rate of the management group reached 83.33%and 82.50%,respectively.There were statistically significant differences between the management group and the control group in the number of attacks,hospitalizations and emergency visits within 1 year(P<0.01).The pulmonary function indexes of FEV1%and PEF%of the management group were higher than those of the control group after 6 and 12 months,and the difference was statistically significant(P<0.01).After 1 year,there were statistically significant differences between the management group and the control group in the level of parental knowledge and medication compliance(P<0.01).Conclusion:The effects of new model of pharmaceutical standardization management for asthma children based on asthma symptom control level grading management system on controlling the clinical symptoms of asthma children,reducing the future risk and improving the quality of life is significant,which can be further promoted as the working mode.
作者
胡文娟
曾娜
孙华君
姜志虎
朱彦
李志玲
Hu Wenjuan;Zeng Na;Sun Huajun;Jiang Zhihu;Zhu Yan;Li Zhiling(Children's Hospital of Shanghai,Children's Hospital of Shanghai Jiao Tong University,Shanghai 200040,China)Abstract:)
出处
《儿科药学杂志》
CAS
2019年第6期34-38,共5页
Journal of Pediatric Pharmacy
基金
上海市交通大学医学院医院药学科研基金项目
编号JDYX2016QN018
上海市卫生计生系统重要薄弱学科建设计划
编号2016ZB0305-01
上海市临床药学重点专科建设项目
关键词
哮喘
分级管理
哮喘症状控制水平分级管理系统
药学规范化管理
新模式
asthma
grading management
asthma symptom control level grading management system
pharmaceutical standardization management
new model
